All Stories

  1. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  2. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  3. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  4. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  5. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  6. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  7. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  8. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  9. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  10. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  11. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  12. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  13. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  14. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  15. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  16. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  17. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  18. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  19. Impact of clonal hematopoiesis on cardiovascular outcomes in cancer patients of the UK Biobank
  20. A genome-wide study of the effect of alcohol consumption on the risk of type 2 diabetes
  21. Data from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  22. Supplementary Figure 1 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  23. Supplementary Figure 1 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  24. Supplementary Figure 2 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  25. Supplementary Figure 2 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  26. Supplementary Table 1 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  27. Supplementary Table 1 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  28. Supplementary Table 10 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  29. Supplementary Table 10 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  30. Supplementary Table 11 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  31. Supplementary Table 11 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  32. Supplementary Table 12 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  33. Supplementary Table 12 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  34. Supplementary Table 13 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  35. Supplementary Table 13 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  36. Supplementary Table 14 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  37. Supplementary Table 14 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  38. Supplementary Table 15 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  39. Supplementary Table 15 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  40. Supplementary Table 16 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  41. Supplementary Table 16 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  42. Supplementary Table 2 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  43. Supplementary Table 2 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  44. Supplementary Table 3 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  45. Supplementary Table 3 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  46. Supplementary Table 4 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  47. Supplementary Table 4 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  48. Supplementary Table 5 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  49. Supplementary Table 5 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  50. Supplementary Table 6 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  51. Supplementary Table 6 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  52. Supplementary Table 7 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  53. Supplementary Table 7 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  54. Supplementary Table 8 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  55. Supplementary Table 8 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  56. Supplementary Table 9 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  57. Supplementary Table 9 from Somatic mosaic chromosomal alterations and death of cardiovascular disease causes among cancer survivors
  58. Prediction of incident atrial fibrillation using deep learning, clinical models, and polygenic scores
  59. A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol
  60. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  61. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  62. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  63. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  64. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  65. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  66. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  67. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  68. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  69. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  70. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  71. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  72. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  73. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  74. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  75. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  76. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  77. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  78. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  79. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  80. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  81. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  82. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  83. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  84. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  85. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  86. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  87. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  88. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  89. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  90. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  91. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  92. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  93. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  94. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  95. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  96. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  97. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  98. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  99. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  100. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  101. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  102. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  103. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  104. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  105. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  106. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  107. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  108. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  109. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  110. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  111. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  112. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  113. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  114. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  115. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  116. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  117. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  118. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  119. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  120. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  121. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  122. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  123. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  124. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  125. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  126. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  127. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  128. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  129. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  130. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  131. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  132. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  133. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  134. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  135. Assessing the role of rare pathogenic variants in heart failure progression by exome sequencing in 8,089 patients
  136. Interplay between hereditary and acquired factors determines the neutrophil counts in older individuals
  137. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  138. Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  139. Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  140. Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  141. Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  142. Figure 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  143. Figure 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  144. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  145. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  146. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  147. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  148. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  149. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  150. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  151. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  152. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  153. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  154. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  155. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  156. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  157. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  158. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  159. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  160. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  161. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  162. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  163. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  164. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  165. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  166. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  167. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  168. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  169. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  170. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  171. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  172. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  173. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  174. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  175. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  176. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  177. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  178. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  179. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  180. Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  181. Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  182. Data from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  183. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  184. Supplementary Figure 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  185. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  186. Supplementary Figure 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  187. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  188. Supplementary Table 1 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  189. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  190. Supplementary Table 10 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  191. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  192. Supplementary Table 11 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  193. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  194. Supplementary Table 12 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  195. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  196. Supplementary Table 13 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  197. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  198. Supplementary Table 14 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  199. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  200. Supplementary Table 15 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  201. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  202. Supplementary Table 16 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  203. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  204. Supplementary Table 2 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  205. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  206. Supplementary Table 3 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  207. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  208. Supplementary Table 4 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  209. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  210. Supplementary Table 5 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  211. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  212. Supplementary Table 6 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  213. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  214. Supplementary Table 7 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  215. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  216. Supplementary Table 8 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  217. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  218. Supplementary Table 9 from Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  219. Somatic Mosaic Chromosomal Alterations and Death of Cardiovascular Disease Causes among Cancer Survivors
  220. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome
  221. Abstract 10075: Hematopoietic Mosaic Chromosomal Alterations and Cardiovascular Disease-Related Deaths Among Cancer Survivors: An Analysis of the UK Biobank
  222. Including diverse and admixed populations in genetic epidemiology research
  223. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites
  224. Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19
  225. Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof‐of‐concept study
  226. Gender matters in heart attack prevention: higher femininity linked to angina diagnosis in men
  227. Comparative Effectiveness and Safety of Low-Dose Oral Anticoagulants in Patients With Atrial Fibrillation
  228. A sex-specific evolutionary interaction between ADCY9 and CETP
  229. Pharmacogenomic study of heart failure and candesartan response from the CHARM programme
  230. The genomics of heart failure: design and rationale of the HERMES consortium
  231. Multitrait GWAS to connect disease variants and biological mechanisms
  232. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
  233. Genetics of symptom remission in outpatients with COVID-19
  234. A sex-specific evolutionary interaction betweenADCY9andCETP
  235. Colchicine for Secondary Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials
  236. Pharmacogenomics of the Efficacy and Safety of Colchicine in COLCOT
  237. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib
  238. Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality
  239. ExPheWas: a browser for gene-based pheWAS associations
  240. Genetics of symptom remission in outpatients with COVID-19
  241. Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women
  242. Comparative effectiveness and safety of high‐dose rivaroxaban and apixaban for atrial fibrillation: A propensity score‐matched cohort study
  243. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect
  244. The associations of hostility and defensiveness with telomere length are influenced by sex and health status
  245. A genetic association study of heart failure: more evidence for the role of BAG3 in idiopathic dilated cardiomyopathy
  246. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
  247. Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure
  248. Statin Initiation: Guideline Concordance and Characteristics of New Users in Quebec, Canada
  249. A genetic model of ivabradine recapitulates results from randomized clinical trials
  250. Multitrait genetic-phenotype associations to connect disease variants and biological mechanisms
  251. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential
  252. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
  253. CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta‐analysis
  254. Heritability of 596 lipid species and genetic correlation with cardiovascular traits in the Busselton Family Heart Study
  255. Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA‐HF trial
  256. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib
  257. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
  258. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation
  259. Inherited Chromosomally Integrated Human Herpesvirus 6 Demonstrates Tissue-Specific RNA Expression In Vivo That Correlates with an Increased Antibody Immune Response
  260. Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes
  261. rs73185306 C/T Is Not a Predisposing Risk Factor for Inherited Chromosomally Integrated Human Herpesvirus 6A/B
  262. Inherited chromosomally integrated HHV-6 demonstrates tissue-specific RNA expressionin vivothat correlates with increased antibody immune response
  263. Publisher Correction: Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
  264. Validation of Genome-Wide Polygenic Risk Scores for Coronary Artery Disease in French Canadians
  265. Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events
  266. Subsequent Event Risk in Individuals With Established Coronary Heart Disease
  267. Lipoprotein (a), arterial inflammation, and PCSK9 inhibition
  268. Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution
  269. Validation of genome-wide polygenic risk scores for coronary artery disease in French Canadians
  270. Biomarkers of dementia in obstructive sleep apnea
  271. Pharmacogenetic content of commercial genome-wide genotyping arrays
  272. Randomized Clinical Trial Needed to Confirm Whether Dalcetrapib Improves Outcomes for Specific ADCY9 Genotype
  273. Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High‐Density Lipoprotein Cholesterol
  274. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A
  275. Protein-Coding Variants Implicate Novel Genes Related to Lipid Homeostasis Contributing to Body Fat Distribution
  276. Sex, drugs, and heart failure: a sex-sensitive review of the evidence base behind current heart failure clinical guidelines
  277. Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study
  278. Pharmacogenomics of blood lipid regulation
  279. A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure
  280. A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention
  281. Nuclear receptor gene polymorphisms and warfarin dose requirements in the Quebec Warfarin Cohort
  282. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
  283. Polygenic determinants in extremes of high-density lipoprotein cholesterol
  284. Exome-wide association study of plasma lipids in >300,000 individuals
  285. Precision medicine to change the landscape of cardiovascular drug development
  286. Impact of Selection Bias on Estimation of Subsequent Event Risk
  287. Identification of the genetic determinants responsible for retinal degeneration in families of Mexican descent
  288. Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies
  289. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions
  290. CKing Precision in the Interpretation of Diagnostic Biomarkers
  291. Diagnosis, Prevalence, Awareness, Treatment, Prevention, and Control of Hypertension in Cameroon: Protocol for a Systematic Review and Meta-Analysis of Clinic-Based and Community-Based Studies
  292. Protein-altering and regulatory genetic variants near GATA4 implicated in bicuspid aortic valve
  293. CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction
  294. Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol
  295. CETP
  296. Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease
  297. Pharmacogenomic approaches to lipid-regulating trials
  298. Polygenic Versus Monogenic Causes of Hypercholesterolemia Ascertained Clinically
  299. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality
  300. Paternal Age Explains a Major Portion of De Novo Germline Mutation Rate Variability in Healthy Individuals
  301. A model to assess the cost–effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradine
  302. Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk population
  303. Meta-analysis of genome-wide association studies of HDL cholesterol response to statins
  304. genipe: an automated genome-wide imputation pipeline with automatic reporting and statistical tools
  305. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation
  306. Whole-genome sequencing in French Canadians from Quebec
  307. Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits
  308. Platelet-Related Variants Identified by Exomechip Meta-analysis in 157,293 Individuals
  309. DNA methylation signature of human fetal alcohol spectrum disorder
  310. Avoidance of Vitamin K−Rich Foods Is Common among Warfarin Users and Translates into Lower Usual Vitamin K Intakes
  311. Pillbox Use and INR Stability in a Prospective Cohort of New Warfarin Users
  312. Methylomic changes during conversion to psychosis
  313. Coding Variation inANGPTL4,LPL,andSVEP1and the Risk of Coronary Disease
  314. A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials
  315. An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance
  316. Testing the role of predicted gene knockouts in human anthropometric trait variation
  317. Resting heart rate as a predictor of aortic valve stenosis progression
  318. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease
  319. Calcium Signaling Pathway GenesRUNX2andCACNA1CAre Associated With Calcific Aortic Valve DiseaseCLINICAL PERSPECTIVE
  320. Will personalized drugs for cardiovascular disease become an option? – Defining ‘Evidence-based personalized medicine’ for its implementation and future use
  321. Impact of regular physical activity on weekly warfarin dose requirement
  322. Mutation Burden of Rare Variants in Schizophrenia Candidate Genes
  323. Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review
  324. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice
  325. Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib
  326. Comparison of Sequencing Based CNV Discovery Methods Using Monozygotic Twin Quartets
  327. CKM and LILRB5 Are Associated With Serum Levels of Creatine Kinase
  328. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
  329. Genetic Markers of Cisplatin-Induced Hearing Loss in Children
  330. Modifiers of (CAG)n instability in Machado–Joseph disease (MJD/SCA3) transmissions: an association study with DNA replication, repair and recombination genes
  331. Development of a broad-based ADME panel for use in pharmacogenomic studies
  332. Lipoprotein(a) Levels, Genotype, and Incident Aortic Valve Stenosis
  333. Novel presenilin mutations within Moroccan patients with Early-Onset Alzheimer’s Disease
  334. Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits
  335. Novel Mutations in the Amyloid Precursor Protein Gene within Moroccan Patients with Alzheimer's Disease
  336. Comparison of genotype clustering tools with rare variants
  337. Cuckoo search epistasis: a new method for exploring significant genetic interactions
  338. Validation of patient-reported warfarin dose in a prospective incident cohort study
  339. Evaluation of Links Between High-Density Lipoprotein Genetics, Functionality, and Aortic Valve Stenosis Risk in Humans
  340. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity
  341. pyGenClean: efficient tool for genetic data clean up before association testing
  342. Erratum: Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
  343. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent
  344. Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children
  345. The Impact of Partial and Complete Loss-of-Function Mutations in Endothelial Lipase on High-Density Lipoprotein Levels and Functionality in Humans
  346. Institutional Profile: The Beaulieu-Saucier Université de Montréal Pharmacogenomics Centre at the Montreal Heart Institute
  347. SRAP Polymorphisms Associated to Cell Wall Degradability in Lignified Stems of Alfalfa
  348. Pooled DNA Resequencing of 68 Myocardial Infarction Candidate Genes in French Canadians
  349. Rare Copy Number Variants Contribute to Congenital Left-Sided Heart Disease
  350. Genetic control of high density lipoprotein-cholesterol in AcB/BcA recombinant congenic strains of mice
  351. Segregation of LIPG, CETP, and GALNT2 Mutations in Caucasian Families with Extremely High HDL Cholesterol
  352. Assessment of Genetic Variability of Cell Wall Degradability for the Selection of Alfalfa with Improved Saccharification Efficiency
  353. PRKCB is associated with calcineurin inhibitor-induced renal dysfunction in heart transplant recipients
  354. Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children
  355. Molecular physiology and breeding at the crossroads of cold hardiness improvement
  356. Risk of congenital heart defects is influenced by genetic variation in folate metabolism
  357. Erratum to: Intron-length polymorphism identifies a Y2K4 dehydrin variant linked to superior freezing tolerance in alfalfa
  358. Validation of warfarin pharmacogenetic algorithms in clinical practice
  359. Intron-length polymorphism identifies a Y2K4 dehydrin variant linked to superior freezing tolerance in alfalfa
  360. Design and rationale of a genetic cohort study on congenital cardiac disease: experiences from a multi-institutional platform in Quebec
  361. Predicting Statin Induced Muscle Toxicity
  362. Fetal Alcohol Spectrum Disorders: Gene-Environment Interactions, Predictive Biomarkers, and the Relationship Between Structural Alterations in the Brain and Functional Outcomes
  363. Familial ventricular aneurysms and septal defects map to chromosome 10p15
  364. Positional cloning of a quantitative trait locus contributing to pain sensitivity: possible mediation by Tyrp1
  365. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura
  366. Direct Measure of the De Novo Mutation Rate in Autism and Schizophrenia Cohorts
  367. Partitioning of copy-number genotypes in pedigrees
  368. Family Study of Restless Legs Syndrome in Quebec, Canada
  369. Mutations in DCC Cause Congenital Mirror Movements
  370. De novo mutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia
  371. Genetic determinants of blood pressure reduction following potassium supplementation: and the candidates are…
  372. Genetics of bronchopulmonary dysplasia in the age of genomics
  373. Testing for Gene-Gene Interaction with AMMI Models
  374. Novel mutations in the sacsin gene in ataxia patients from Maritime Canada
  375. Genetic Studies
  376. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy
  377. Genetic Modulation of Brugada Syndrome by a Common Polymorphism
  378. Application of principal component analysis to pharmacogenomic studies in Canada
  379. Association between cervical and intracranial dimensions and syringomyelia in the cavalier King Charles spaniel
  380. Mutation in Pyrroline-5-Carboxylate Reductase 1 Gene in Families with Cutis Laxa Type 2
  381. Application of Homozygosity Haplotype Analysis to Genetic Mapping with High-Density SNP Genotype Data
  382. Genetic predictors of depressive symptoms in cardiac patients
  383. The challenge of detecting epistasis (G×G Interactions): Genetic Analysis Workshop 16
  384. Autosomal-dominant locus for restless legs syndrome in French-Canadians on chromosome 16p12.1
  385. Génome Québec & Montreal Heart Institute Pharmacogenomics Centre: a translational pharmacogenomics platform – from R&D to the clinic
  386. Mutations in the calcium-related gene IL1RAPL1 are associated with autism
  387. A survey of the personalized medicine landscape
  388. Effects of AGTR1 A1166C Gene Polymorphism in Patients with Heart Failure Treated with Candesartan
  389. Ten renin-angiotensin system-related gene polymorphisms in maximally treated Canadian Caucasian patients with heart failure
  390. A novel locus for idiopathic generalized epilepsy in French-Canadian families maps to 10p11
  391. No evidence that skewing of X chromosome inactivation patterns is transmitted to offspring in humans
  392. The Genetics of Congenital Amusia (Tone Deafness): A Family-Aggregation Study
  393. Mutations in the UBIAD1 Gene, Encoding a Potential Prenyltransferase, Are Causal for Schnyder Crystalline Corneal Dystrophy
  394. Syringomyelia in cavalier King Charles spaniels: the relationship between syrinx dimensions and pain
  395. Obesity and TCF7L2 variants' additive effect on type 2 diabetes risk in cardiac patients
  396. Molecular genetic studies of DMT1 on 12q in French‐Canadian restless legs syndrome patients and families
  397. Loss-of-function genetic diseases and the concept of pharmaceutical targets
  398. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations
  399. Lamin A/C mutations associated with familial and sporadic cases of dilated cardiomyopathy in Koreans
  400. Multistage designs in the genomic era: Providing balance in complex disease studies
  401. A novel autosomal dominant restless legs syndrome locus maps to chromosome 20p13
  402. Bootstrap Inference with Neural-Network Modeling for Gene-Disease Association Testing
  403. A new locus for autosomal dominant intracranial aneurysm, ANIB4, maps to chromosome 5p15.2-14.3
  404. Human monogenic disorders — a source of novel drug targets
  405. Common Genetic Vulnerability to Depressive Symptoms and Coronary Artery Disease: A Review and Development of Candidate Genes Related to Inflammation and Serotonin
  406. Autism spectrum disorders associated with X chromosome markers in French-Canadian males
  407. A Variant in XPNPEP2 Is Associated with Angioedema Induced by Angiotensin I–Converting Enzyme Inhibitors
  408. Analysis of microsatellite markers and single nucleotide polymorphisms in candidate genes for susceptibility to bipolar affective disorder in the chromosome 12Q24.31 region
  409. Chromosome 11-q24 region in Tourette syndrome: Association and linkage disequilibrium study in the French Canadian population
  410. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease
  411. The 14q restless legs syndrome locus in the French Canadian population
  412. Identification of a Novel Gene (HSN2) Causing Hereditary Sensory and Autonomic Neuropathy Type II through the Study of Canadian Genetic Isolates
  413. Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
  414. AnALS2gene mutation causes hereditary spastic paraplegia in a Pakistani kindred
  415. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy
  416. Fine mapping the candidate region for peripheral neuropathy with or without agenesis of the corpus callosum in the French Canadian population
  417. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives
  418. Clouston hidrotic ectodermal dysplasia (HED): genetic homogeneity, presence of a founder effect in the French Canadian population and fine genetic mapping
  419. Genomic structure of the human GT334 (EHOC-1) gene mapping to 21q22.3